Jinendra Qualipharm Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 16-07-2024
- Paid Up Capital ₹ 0.43 M
as on 16-07-2024
- Company Age 15 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -23.03%
(FY 2023)
- Profit -33.61%
(FY 2023)
- Ebitda -32.82%
(FY 2023)
- Net Worth 39.95%
(FY 2023)
- Total Assets 31.95%
(FY 2023)
About Jinendra Qualipharm
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.43 M, as per Ministry of Corporate Affairs (MCA) records.
Aayush Jain, Ajit Jain, and Anju Jain serve as directors at the Company.
- CIN/LLPIN
U24100MH2009PTC196480
- Company No.
196480
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Oct 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Jinendra Qualipharm?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aayush Jain  | Director | 27-Jan-2015 | Current |
| Ajit Jain | Director | 14-Jun-2022 | Current |
| Anju Jain | Director | 27-Jan-2015 | Current |
Financial of Jinendra Qualipharm.
Jinendra Qualipharm Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 23.03% decrease. The company also saw a substantial fall in profitability, with a 33.61% decrease in profit. The company's net worth Soared by an impressive increase of 39.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jinendra Qualipharm?
In 2023, Jinendra Qualipharm had a promoter holding of 23.26% and a public holding of 76.74%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Qualigens Pharma Private LimitedActive 11 years 2 monthsAayush Jain and Ajit Jain are mutual person
- Ajaayu Trading And Consultancy Private LimitedActive 24 years 11 months
Aayush Jain and Anju Jain are mutual person
- Evergrow Marketing Private LimitedActive 24 years 9 months
Aayush Jain and Anju Jain are mutual person
- Munisuvrat Consultancy Private LimitedActive 12 years 3 months
Aayush Jain and Anju Jain are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Jinendra Qualipharm?
Unlock and access historical data on people associated with Jinendra Qualipharm, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jinendra Qualipharm, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jinendra Qualipharm's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
